Found 206 clinical trials
Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG. Clinical trial NCT02449239, VB4-845-02-IIIA.
Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of
- 177 views
- 02 Sep, 2021
- 1 location
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)
- 332 views
- 08 Nov, 2020
- 1 location
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Investigational Product in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Investigational Product in Patients With Systemic Lupus Erythematosus (SLE)
- 674 views
- 08 Nov, 2020
- 1 location
Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus-Calmette-Guerin
(BCG) unresponsive disease, with either carcinoma in situ with or without Ta/T1 disease
- 0 views
- 03 Sep, 2021
- 36 locations
NORTH-REG Dwell-Time Study
Previous studies show that the majority NMIBC patients experience side effects to BCG and therefore terminate the instillations before completing all planned instillations. This will increase their risk of recurrence and potential cystectomy. The purpose of this study is to investigate if NMIBC patients who experience severe side effects to …
- 0 views
- 14 Feb, 2021
- 11 locations
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
The primary objective of this study is to compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in
- 46 views
- 07 Nov, 2020
- 2 locations
Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery
the side effects of doxorubicin hydrochloride liposome and to see how well it works in treating women with ductal carcinoma in situ undergoing surgery.
- 0 views
- 07 Nov, 2020
- 1 location
A Study to Evaluate Safety Efficacy of Intralesional Injection of STP705 in Patients With isSCC
(in situ) skin cancer (isSCC).
- 0 views
- 02 Jun, 2021
- 1 location
Study of CG0070 Given in Combination With Pembrolizumab in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
(NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease.
- 0 views
- 04 Sep, 2021
- 22 locations